資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34396
|
| 標題: | Imaging biomarkers for evaluating tumor response: RECIST and beyond |
| 作者: | Ko, Ching-Chung
Yeh, Lee-Ren
Kuo, Yu-Ting
Chen, Jeon-Hor |
| 貢獻者: | Chi Mei Med Ctr, Dept Med Imaging
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
I Shou Univ, E DA Hosp, Dept Radiol
Kaohsiung Med Univ Hosp, Dept Med Imaging
Univ Calif Irvine, Dept Radiol Sci, Tu & Yuan Ctr Funct Oncoimaging |
| 關鍵字: | RECIST
Imaging biomarker
Tumor response |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:49:31 (UTC+8) |
| 出版者: | BMC |
| 摘要: | Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for assessment of treatment response in solid tumors. Morphologic change of tumor size evaluated by RECIST is often correlated with survival length and has been considered as a surrogate endpoint of therapeutic efficacy. However, the detection of morphologic change alone may not be sufficient for assessing response to new anti-cancer medication in all solid tumors. During the past fifteen years, several molecular-targeted therapies and immunotherapies have emerged in cancer treatment which work by disrupting signaling pathways and inhibited cell growth. Tumor necrosis or lack of tumor progression is associated with a good therapeutic response even in the absence of tumor shrinkage. Therefore, the use of unmodified RECIST criteria to estimate morphological changes of tumor alone may not be sufficient to estimate tumor response for these new anti-cancer drugs. Several studies have reported the low reliability of RECIST in evaluating treatment response in different tumors such as hepatocellular carcinoma, lung cancer, prostate cancer, brain glioma, bone metastasis, and lymphoma. There is an increased need for new medical imaging biomarkers, considering the changes in tumor viability, metabolic activity, and attenuation, which are related to early tumor response. Promising imaging techniques, beyond RECIST, include dynamic contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), diffusion-weight imaging (DWI), magnetic resonance spectroscopy (MRS), and (18) F-fluorodeoxyglucose (FDG) positron emission tomography (PET). This review outlines the current RECIST with their limitations and the new emerging concepts of imaging biomarkers in oncology. |
| 關聯: | BIOMARK RES, v.9, n.1 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 162 | 檢視/開啟 | | s40364-021-00306-8.pdf | | 4628Kb | Adobe PDF | 103 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
